5:30 PM
 | 
Mar 14, 2013
 |  BC Extra  |  Clinical News

FDA investigating pancreatic toxicity of antidiabetics

FDA said it is evaluating the potential pancreatic toxicity of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The agency said unpublished data from undisclosed academics showed the Type II...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >